Radiolabeled fibroblast activation protein inhibitors in the evaluation of myocardial fibrosis

To the Editor:Myocardial fibrosis is a common pathological process of heart failure(HF).The methods for non-invasive diagnosis of myocardial fibrosis are finite.Currently,cardiac magnetic resonance(CMR)that serves as the gold standard for determining fibrotic lesions is able to offer high spatial resolution and validate myocardial fibrosis.However,the extracellular volume fraction measured with CMR can even increase in other pathologies such as inflammatory edema or protein deposition;thus,a new complementary imaging modality to detect cardiac fibrosis is necessary.